Icaritin Inhibits Malignant Progression and Enhances Ferroptosis and Bortezomib Sensitivity by Suppressing HSP90AA1 Expression in Multiple Myeloma
Chemical Biology & Drug Design · 2026-04 · 107 (4)
DOI: 10.1111/cbdd.70284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 13.04.2026. Verfasst von Lin Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional …. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, HSP90 Heat-Shock Proteins, Ferroptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Specialized Research Topics of Henan Pronincial Scientific Research in Traditional Chinese Medicine.
Abstract (Originalsprache)
Multiple myeloma (MM) is a hematologic malignancy commonly treated with bortezomib (BTZ). However, treatment efficacy is often limited by the development of BTZ resistance. Icaritin has demonstrated broad anti‐tumor activities. This study aimed to investigate the effect of Icaritin on the malignant progression of MM and its potential to overcome BTZ resistance. The anti‐MM activity of Icaritin was evaluated through a series of experimental approaches, including cell counting kit 8, flow cytometry, 5‐ethynyl‐2′‐deoxyuridine, network pharmacology, molecule docking, reverse transcription‐quantitative polymerase chain reaction, Co‐Immunoprecipitation (CoIP), and western blot. Icaritin suppressed MM cell viability and proliferation, induced ferroptosis, and enhanced cellular sensitivity to BTZ. Moreover, Icaritin inhibited HSP90α family 1 (HSP90AA1) protein expression via promoting ubiquitination. HSP90AA1 facilitated MM cell proliferation, suppressed ferroptosis, and attenuated BTZ sensitivity. Notably, Icaritin promoted MM cell ferroptosis and BTZ sensitivity by inhibiting HSP90AA1. In vivo, Icaritin enhanced the sensitivity of tumor cells to BTZ. Icaritin suppresses malignant progression, induces ferroptosis, and enhances BTZ sensitivity in MM by inhibiting HSP90AA1. These findings provide a novel theoretical basis for Icaritin treatment of MM and regulation of BTZ sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Institute of Hematology, Henan University of Tradit…
- The Second Clinical Medical School, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China.
ORCID-Profile: Lin Shi, Xueying Wang
Förderung
- Specialized Research Topics of Henan Pronincial Scientific Research in Traditional Chinese Medicine
Zitieren
APA
Shi, L., Lv, D., Wang, X., Zhang, K., Feng, L., Zhang, R., & Zhao, J. (2026). Icaritin Inhibits Malignant Progression and Enhances Ferroptosis and Bortezomib Sensitivity by Suppressing HSP90AA1 Expression in Multiple Myeloma. Chemical Biology & Drug Design, 107(4). https://doi.org/10.1111/cbdd.70284
Vancouver
Shi L, Lv D, Wang X, Zhang K, Feng L, Zhang R, et al. Icaritin Inhibits Malignant Progression and Enhances Ferroptosis and Bortezomib Sensitivity by Suppressing HSP90AA1 Expression in Multiple Myeloma. Chemical Biology & Drug Design. 2026;107(4). doi:10.1111/cbdd.70284
BibTeX
@article{Shi2026,
author = {Shi, Lin and Lv, Dianliang and Wang, Xueying and Zhang, Kuanshun and Feng, Lei and Zhang, Runfang and Zhao, Jiangshan},
title = {Icaritin Inhibits Malignant Progression and Enhances Ferroptosis and Bortezomib Sensitivity by Suppressing HSP90AA1 Expression in Multiple Myeloma},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {4},
doi = {10.1111/cbdd.70284}
}
EUVIMED